KR101424046B1 - 심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아미노 유도체 - Google Patents

심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아미노 유도체 Download PDF

Info

Publication number
KR101424046B1
KR101424046B1 KR1020087027712A KR20087027712A KR101424046B1 KR 101424046 B1 KR101424046 B1 KR 101424046B1 KR 1020087027712 A KR1020087027712 A KR 1020087027712A KR 20087027712 A KR20087027712 A KR 20087027712A KR 101424046 B1 KR101424046 B1 KR 101424046B1
Authority
KR
South Korea
Prior art keywords
hydroxy
methylandrostane
delete delete
rti
androstane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087027712A
Other languages
English (en)
Korean (ko)
Other versions
KR20080111532A (ko
Inventor
알베르토 체리
마르코 토리
실비아 아르마롤리
레오나르도 반피
기우세페 비안치
기우리오 카르자나
패트리지아 페라리
로사마리아 미켈레티
시모나 스푸토레
마리아 피아 자파비그나
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20080111532A publication Critical patent/KR20080111532A/ko
Application granted granted Critical
Publication of KR101424046B1 publication Critical patent/KR101424046B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087027712A 2006-04-13 2007-04-11 심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아미노 유도체 Expired - Fee Related KR101424046B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06112598.5 2006-04-13
EP06112598 2006-04-13
PCT/EP2007/053524 WO2007118832A2 (en) 2006-04-13 2007-04-11 Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders

Publications (2)

Publication Number Publication Date
KR20080111532A KR20080111532A (ko) 2008-12-23
KR101424046B1 true KR101424046B1 (ko) 2014-07-28

Family

ID=37268538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027712A Expired - Fee Related KR101424046B1 (ko) 2006-04-13 2007-04-11 심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아미노 유도체

Country Status (16)

Country Link
US (1) US8609644B2 (enExample)
EP (1) EP2004668B1 (enExample)
JP (1) JP5438503B2 (enExample)
KR (1) KR101424046B1 (enExample)
CN (1) CN101466725B (enExample)
AR (1) AR060427A1 (enExample)
AU (1) AU2007239518B2 (enExample)
BR (1) BRPI0709943A2 (enExample)
CA (1) CA2649175C (enExample)
EA (1) EA015257B1 (enExample)
ES (1) ES2405625T3 (enExample)
MX (1) MX2008012942A (enExample)
PL (1) PL2004668T3 (enExample)
PT (1) PT2004668E (enExample)
TW (1) TWI392682B (enExample)
WO (1) WO2007118832A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168621B2 (en) 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
WO2008067450A2 (en) * 2006-11-30 2008-06-05 Endece, Llc 6-alkoxyalkyl estradiol derivatives and methods of use
HUE027408T2 (en) * 2009-03-23 2016-10-28 Sigma Tau Ind Farmaceuti Proteinuria, 5ß, 14β-androstane derivatives for the treatment of glomerulosclerosis and renal failure
WO2010149666A1 (en) 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
CN109219612A (zh) * 2016-03-02 2019-01-15 帕西昂奥地利有限两合公司 制备17(20)-烯b-开环类固醇的方法和中间体
CA3138176A1 (en) * 2019-04-27 2020-11-05 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
ES2970792T3 (es) * 2019-10-09 2024-05-30 Windtree Therapeutics Inc Derivados de androstano con actividad como estimuladores puros o predominantemente puros de SERCA2A para el tratamiento de la insuficiencia cardíaca
CN111040012B (zh) * 2019-12-27 2022-04-15 山东安弘制药有限公司 一种依西美坦螺环氧乙烷杂质的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB868303A (en) * 1956-09-08 1961-05-17 Syntex Sa New cyclopentanophenanthrene derivatives and process for the production thereof
BE589491A (enExample) * 1959-04-10
US3210386A (en) 1961-01-09 1965-10-05 Upjohn Co 3-aminoethers of 3beta-hydroxy androstanes
DE1187236B (de) 1961-03-28 1965-02-18 Searle & Co Verfahren zur Herstellung von 17beta-Aminosteroiden
GB1042292A (en) * 1961-11-08 1966-09-14 Organon Labor Ltd 5ª‡-hydroxy-6ª‰-amino steroids and the preparation thereof
US3120515A (en) * 1962-05-31 1964-02-04 Sterling Drug Inc 5-cyano steroids, their preparation, and derivatives thereof
US5144017A (en) * 1988-07-13 1992-09-01 University Of Manitoba Compounds that bind to digitalis receptor
US5522847A (en) * 1993-06-18 1996-06-04 Kalis; Amy G. Pacifier with novelty electronic display
US5662685A (en) * 1996-08-13 1997-09-02 Uhler; Gary S. Sound producing pacifier
DE19633349A1 (de) * 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
US6066161A (en) * 1997-07-26 2000-05-23 Parella; Nicole D. X. Baby pacifier apparatus with remote control locator
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
PL1689410T3 (pl) * 2003-11-26 2008-10-31 Bayer Schering Pharma Ag Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sergio De Munari 등. J. Med. Chem. Vol. 46, No. 17, 페이지 3644-3654 (2003.) *
유럽 특허출원공개공보 EP0825197(1998.02.25.) *

Also Published As

Publication number Publication date
AU2007239518B2 (en) 2012-03-15
JP2009533392A (ja) 2009-09-17
WO2007118832A3 (en) 2008-04-17
EA015257B1 (ru) 2011-06-30
PL2004668T3 (pl) 2013-07-31
BRPI0709943A2 (pt) 2011-08-02
EP2004668B1 (en) 2013-03-13
MX2008012942A (es) 2008-10-17
ES2405625T3 (es) 2013-05-31
AU2007239518A2 (en) 2008-11-27
US8609644B2 (en) 2013-12-17
HK1134821A1 (en) 2010-05-14
JP5438503B2 (ja) 2014-03-12
AU2007239518A1 (en) 2007-10-25
WO2007118832A2 (en) 2007-10-25
KR20080111532A (ko) 2008-12-23
TW200804406A (en) 2008-01-16
PT2004668E (pt) 2013-04-30
CN101466725B (zh) 2014-06-25
US20110053902A1 (en) 2011-03-03
CN101466725A (zh) 2009-06-24
CA2649175A1 (en) 2007-10-25
AR060427A1 (es) 2008-06-18
EA200870434A1 (ru) 2009-04-28
CA2649175C (en) 2015-01-27
TWI392682B (zh) 2013-04-11
EP2004668A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
KR101424046B1 (ko) 심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아미노 유도체
KR101411280B1 (ko) 심장혈관계 장애를 위한 약물로서 안드로스탄 및 안드로스텐의 아자헤테로사이클일 유도체
EP2032593B1 (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
HK1134821B (en) Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
HK1134820B (en) Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20170711

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180723